A phase I/II study of dasatinib in relapsed or refractory non-Hodgkin's lymphoma (NHL) (BMS [Bristol-Myers Squibb] protocol 180129).

Trial Profile

A phase I/II study of dasatinib in relapsed or refractory non-Hodgkin's lymphoma (NHL) (BMS [Bristol-Myers Squibb] protocol 180129).

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Dasatinib (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Aug 2017 Planned End Date changed from 1 Sep 2015 to 1 May 2018.
    • 15 Aug 2017 Planned primary completion date changed from 1 Sep 2015 to 1 Apr 2018.
    • 07 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top